Biomerica Stock Price, News & Analysis (NASDAQ:BMRA)

$4.95 -0.18 (-3.51 %)
(As of 01/16/2018 02:48 AM ET)
Previous Close$5.13
Today's Range$4.81 - $5.29
52-Week Range$1.93 - $9.32
Volume120,000 shs
Average Volume457,411 shs
Market Capitalization$42.22 million
P/E Ratio-41.25
Dividend YieldN/A
Beta-0.53

About Biomerica (NASDAQ:BMRA)

Biomerica, Inc. is a biomedical company, which develops, manufactures and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The Company's medical diagnostic products are sold around the world in over two markets, including clinical laboratories and point of care (physicians' offices and over-the-counter drugstores). The Company operates in Europe, the United States, Asia, South America, the Middle East and other foreign countries. The Company's diagnostic test kits are used to analyze blood, urine or fecal specimens from patients in the diagnosis of various diseases and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which exist in the human body in various concentrations. The Company primarily focuses on products for gastrointestinal (GI), food intolerances, diabetes and esoteric tests. The Company's diagnostic products use immunoassay technology.

Receive BMRA News and Ratings via Email

Sign-up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Equipment, Supplies & Distribution
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BMRA
CUSIPN/A
Phone949-645-2111

Debt

Debt-to-Equity RatioN/A
Current Ratio6.73%
Quick Ratio3.84%

Price-To-Earnings

Trailing P/E Ratio-41.25
Forward P/E Ratio-30.94
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.79 million
Price / Sales7.29
Cash FlowN/A
Price / CashN/A
Book Value$0.53 per share
Price / Book9.34

Profitability

Trailing EPS($0.12)
Net Income$-900,000.00
Net Margins-18.19%
Return on Equity-22.82%
Return on Assets-20.22%

Miscellaneous

Employees39
Outstanding Shares8,530,000

Biomerica (NASDAQ:BMRA) Frequently Asked Questions

What is Biomerica's stock symbol?

Biomerica trades on the NASDAQ under the ticker symbol "BMRA."

How were Biomerica's earnings last quarter?

Biomerica, Inc. (NASDAQ:BMRA) posted its earnings results on Monday, October, 16th. The company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.03) by $0.01. The firm earned $1.44 million during the quarter, compared to analyst estimates of $1.52 million. Biomerica had a negative net margin of 18.19% and a negative return on equity of 22.82%. View Biomerica's Earnings History.

Where is Biomerica's stock going? Where will Biomerica's stock price be in 2018?

1 equities research analysts have issued 12 month price objectives for Biomerica's stock. Their predictions range from $7.50 to $7.50. On average, they anticipate Biomerica's share price to reach $7.50 in the next year. View Analyst Ratings for Biomerica.

Who are some of Biomerica's key competitors?

Who are Biomerica's key executives?

Biomerica's management team includes the folowing people:

  • Zackary S. Irani, Chairman of the Board, Chief Executive Officer (Age 51)
  • Francis E. Capitanio, President (Age 73)
  • Janet Moore, Chief Financial Officer, Treasurer, Secretary, Director (Age 66)
  • Allen C. Barbieri, Independent Director (Age 59)
  • Francis R. Cano Ph.D., Independent Director (Age 70)
  • Jane F. Emerson M.D. Ph.D., Independent Director (Age 63)
  • Mark A. Sirgo, Independent Director (Age 64)

How do I buy Biomerica stock?

Shares of Biomerica can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biomerica's stock price today?

One share of Biomerica stock can currently be purchased for approximately $4.95.

How big of a company is Biomerica?

Biomerica has a market capitalization of $42.22 million and generates $5.79 million in revenue each year. The company earns $-900,000.00 in net income (profit) each year or ($0.12) on an earnings per share basis. Biomerica employs 39 workers across the globe.

How can I contact Biomerica?

Biomerica's mailing address is 17571 Von Karman Avenue, Irvine CA, 92614. The company can be reached via phone at 949-645-2111.


MarketBeat Community Rating for Biomerica (BMRA)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  35 (Vote Outperform)
Underperform Votes:  28 (Vote Underperform)
Total Votes:  63
MarketBeat's community ratings are surveys of what our community members think about Biomerica and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Biomerica (NASDAQ:BMRA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyN/AN/AN/A
Consensus Rating Score: 3.00N/AN/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.50N/AN/AN/A
Price Target Upside: 87.97% upsideN/AN/AN/A

Biomerica (NASDAQ:BMRA) Consensus Price Target History

Price Target History for Biomerica (NASDAQ:BMRA)

Biomerica (NASDAQ:BMRA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/4/2018B. RileyInitiated CoverageBuy -> Buy$7.50HighView Rating Details
(Data available from 1/16/2016 forward)

Earnings

Biomerica (NASDAQ:BMRA) Earnings History and Estimates Chart

Earnings by Quarter for Biomerica (NASDAQ:BMRA)

Biomerica (NASDAQ BMRA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/16/2017Q1 2018($0.03)($0.02)$1.52 million$1.44 millionViewN/AView Earnings Details
8/30/2017Q4 2017($0.02)($0.04)ViewN/AView Earnings Details
4/14/2017Q3 2017($0.03)($0.04)ViewN/AView Earnings Details
1/17/2017Q2 2017($0.03)($0.02)$1.17 million$1.43 millionViewN/AView Earnings Details
10/17/2016Q1 2017($0.03)($0.01)ViewN/AView Earnings Details
8/30/2016Q4 2016($0.01)($0.16)ViewN/AView Earnings Details
4/14/2016Q3 2016($0.02)($0.02)ViewN/AView Earnings Details
1/14/2016Q2 2016($0.02)($0.01)ViewN/AView Earnings Details
10/15/2015Q1 2016($0.02)($0.01)$1.32 million$1.29 millionViewN/AView Earnings Details
9/1/2015Q4 2015$0.03ViewN/AView Earnings Details
4/15/2015Q3 2015($0.01)($0.02)$1.50 million$1.30 millionViewN/AView Earnings Details
1/15/2015Q2 2015($0.01)($0.03)$1.40 million$1.13 millionViewN/AView Earnings Details
10/16/2014Q1 2015($0.03)($0.03)$1.24 million$1.03 millionViewN/AView Earnings Details
9/2/2014Q4 2014$0.02$0.02$1.43 million$1.68 millionViewN/AView Earnings Details
1/15/2014Nov 2013($0.01)($0.03)ViewN/AView Earnings Details
10/15/2013Q1 2014($0.02)ViewN/AView Earnings Details
8/29/2013Q4 2013$0.01ViewN/AView Earnings Details
4/15/2013Q3 2013$0.03($0.01)ViewN/AView Earnings Details
1/14/2013Q2 2013$0.03ViewN/AView Earnings Details
10/15/2012Q1 2013$0.04ViewN/AView Earnings Details
8/29/2012Q4 2012$0.01ViewN/AView Earnings Details
4/17/2012Q3 2012$0.03ViewN/AView Earnings Details
1/17/2012Q2 2012$0.03ViewN/AView Earnings Details
10/18/2011Q1 2012$0.02ViewN/AView Earnings Details
8/30/2011Q4 2011$0.01ViewN/AView Earnings Details
4/15/2011Q3 2011$0.01ViewN/AView Earnings Details
4/15/2010Q3 2010$0.02ViewN/AView Earnings Details
1/19/2010Q2 2010($0.05)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Biomerica (NASDAQ:BMRA) Earnings Estimates

2018 EPS Consensus Estimate: ($0.16)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.03)($0.03)($0.03)
Q2 20182($0.04)($0.03)($0.04)
Q3 20182($0.06)($0.04)($0.05)
Q4 20182($0.06)($0.03)($0.05)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Biomerica (NASDAQ:BMRA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Biomerica (NASDAQ BMRA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 26.30%
Institutional Ownership Percentage: 0.79%
Insider Trades by Quarter for Biomerica (NASDAQ:BMRA)

Biomerica (NASDAQ BMRA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/27/2017Francis E CapitanioPresidentSell15,000$2.46$36,900.00102,000View SEC Filing  
1/4/2017Janet MooreCFOSell4,500$2.20$9,900.00145,220View SEC Filing  
12/22/2016Janet MooreCFOSell9,780$2.18$21,320.40142,000View SEC Filing  
12/12/2016Francis E CapitanioPresidentSell9,351$2.77$25,902.2796,351View SEC Filing  
12/8/2016Francis E CapitanioPresidentSell10,649$2.89$30,775.6190,649View SEC Filing  
11/14/2016Zackary S IraniCEOBuy400$1.94$776.00781,200View SEC Filing  
11/8/2016Zackary S IraniCEOBuy500$1.74$870.00781,000View SEC Filing  
11/4/2016Zackary S IraniCEOBuy1,000$1.95$1,950.00780,600View SEC Filing  
10/20/2016Francis E CapitanioPresidentSell10,000$2.68$26,800.0082,000View SEC Filing  
10/3/2016Jane EmersonDirectorBuy1,000$2.80$2,800.0021,000View SEC Filing  
9/7/2016Zackary S IraniCEOBuy199$2.65$527.35779,600View SEC Filing  
8/12/2016Janet MooreCFOBuy2,200$2.98$6,556.00121,000View SEC Filing  
8/12/2016Zackary S IraniInsiderBuy3,166$2.98$9,434.68776,435View SEC Filing  
8/11/2016Zackary S IraniCEOBuy3,700$2.88$10,656.00773,035View SEC Filing  
8/10/2016Zackary S IraniCEOBuy1,000$2.72$2,720.00771,935View SEC Filing  
8/9/2016Allen BarbieriDirectorBuy3,000$2.54$7,620.0099,889View SEC Filing  
8/5/2016Francis CanoDirectorBuy16,300$2.37$38,631.0082,100View SEC Filing  
8/3/2016Mark A SirgoDirectorBuy4,000$2.05$8,200.0012,000View SEC Filing  
8/3/2016Zackary S IraniCEOBuy2,609$2.10$5,478.90769,926View SEC Filing  
8/2/2016Mark A SirgoDirectorBuy8,000$1.97$15,760.002,000View SEC Filing  
8/1/2016Zackary S IraniCEOBuy5,400$1.88$10,152.00765,926View SEC Filing  
5/16/2016Francis E CapitanioPresidentSell20,000$1.50$30,000.0087,000View SEC Filing  
11/13/2015Zackary S IraniCEOBuy5,000$0.83$4,150.00711,526View SEC Filing  
6/8/2015Zackary S IraniCEOBuy3,000$1.08$3,240.00View SEC Filing  
5/22/2015Zackary S IraniCEOBuy2,000$0.85$1,700.00View SEC Filing  
5/11/2015Zackary S IraniCEOBuy18,000$0.91$16,380.00View SEC Filing  
9/6/2012Zackary S IraniCEOBuy7,000$0.70$4,900.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Biomerica (NASDAQ BMRA) News Headlines

Source:
DateHeadline
Biomerica, Inc. (BMRA) Announces China FDA Approval of Colorectal Screening Test to help Identify Early Warning Signs of Colorectal CancerBiomerica, Inc. (BMRA) Announces China FDA Approval of Colorectal Screening Test to help Identify Early Warning Signs of Colorectal Cancer
www.streetinsider.com - January 11 at 9:23 AM
BRIEF-China FDA Approves Biomerica Colorectal Screening Test To Help Identify The Early Warning Signs Of Colorectal CancerBRIEF-China FDA Approves Biomerica Colorectal Screening Test To Help Identify The Early Warning Signs Of Colorectal Cancer
www.reuters.com - January 10 at 5:39 PM
China Food and Drug Administration (CFDA) approves Biomerica colorectal screening test to help identify the early warning signs of colorectal cancerChina Food and Drug Administration (CFDA) approves Biomerica colorectal screening test to help identify the early warning signs of colorectal cancer
finance.yahoo.com - January 10 at 9:11 AM
Biomerica Inc (NASDAQ:BMRA): Poised For Long-Term Success?Biomerica Inc (NASDAQ:BMRA): Poised For Long-Term Success?
finance.yahoo.com - January 9 at 9:10 AM
Biomerica Signs Agreements with Beth Israel Deaconess & University of Michigan to Initiate Clinical Study for First of a Kind, Irritable Bowel Syndrome (IBS) Diagnostic Guided Therapy (DGT)Biomerica Signs Agreements with Beth Israel Deaconess & University of Michigan to Initiate Clinical Study for First of a Kind, Irritable Bowel Syndrome (IBS) Diagnostic Guided Therapy (DGT)
finance.yahoo.com - January 8 at 5:50 PM
Q2 2018 Earnings Estimate for Biomerica, Inc. (BMRA) Issued By B. RileyQ2 2018 Earnings Estimate for Biomerica, Inc. (BMRA) Issued By B. Riley
www.americanbankingnews.com - January 8 at 6:38 AM
Is Biomerica Inc (NASDAQ:BMRA) Thriving Or Barely Surviving In The Healthcare Sector?Is Biomerica Inc (NASDAQ:BMRA) Thriving Or Barely Surviving In The Healthcare Sector?
finance.yahoo.com - January 2 at 9:06 AM
Does Biomerica Inc’s (NASDAQ:BMRA) Earnings Growth Make It An Outperformer?Does Biomerica Inc’s (NASDAQ:BMRA) Earnings Growth Make It An Outperformer?
finance.yahoo.com - December 25 at 7:19 PM
What You Must Know About Biomerica Inc’s (BMRA) Financial HealthWhat You Must Know About Biomerica Inc’s (BMRA) Financial Health
finance.yahoo.com - December 7 at 6:13 PM
BRIEF-Biomerica Enters Into At Market Issuance Sales Agreement With B. Riley FBRBRIEF-Biomerica Enters Into At Market Issuance Sales Agreement With B. Riley FBR
www.reuters.com - December 4 at 9:01 AM
Biomerica (BMRA) Cut to Sell at ValuEngineBiomerica (BMRA) Cut to Sell at ValuEngine
www.americanbankingnews.com - December 3 at 9:26 PM
Biomerica Announces Enrollment of First Patient for H. Pylori Clinical Studies at the University of Southern CaliforniaBiomerica Announces Enrollment of First Patient for H. Pylori Clinical Studies at the University of Southern California
finance.yahoo.com - November 20 at 5:50 PM

SEC Filings

Biomerica (NASDAQ:BMRA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Biomerica (NASDAQ:BMRA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Biomerica (NASDAQ BMRA) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.